Efficiency and safety in vivo studies of a promising re-engineered antibody fragment derived from bapineuzumab to cure Alzheimer's disease

Project Details

StatusFinished
Effective start/end date30/07/1529/07/17

Funding

  • Agency for Management of University and Research Grants (AGAUR): €100,000.00
  • European Regional Development Fund (FEDER)